MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- PANACEA BIOTECH
PANACEA BIOTECH Share Price (PANB)
Here is the latest stock price and chart of Panacea Biotech. For more details, see the Panacea Biotech company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Just Released: The No. 1 Stock to Buy in 2020
| Live BSE Quotes | Jan 29, 2020 03:37:00 PM | ||
|---|---|---|---|
| Price (Rs)130.50 | Open (Rs) 130.70 | High (Rs) 134.20 | Low (Rs) 130.30 |
| % Change-0.61 | Volume 113 | Value (Rs) 14,747 | 52-Week H/L 219.00 / 111.00 |
| Live NSE Quotes | Jan 29, 2020 3:29:58 PM | ||
|---|---|---|---|
| Price (Rs)130.40 | Open (Rs) 131.50 | High (Rs) 134.80 | Low (Rs) 130.00 |
| % Change-0.08 | Volume 27,355 | Value (Rs) 3,588,702 | 52-Week H/L 215.95 / 110.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 12.11 | P/E Ratio (x) 10.78 | Market Cap (Rs m) 7,993.13 | P/BV (x) 2.28 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
PANACEA BIOTECH Share Price Today:
PANACEA BIOTECH last traded price was down 0.6% to Rs 130.5 on the BSE. On the NSE, PANACEA BIOTECH last traded price was down 0.1% to Rs 130.4. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.1%. And the benchmark S&P BSE SENSEX was at 41,204.4 (up 0.6%).
Over the last 30 days, the PANACEA BIOTECH share price is up 0.1%. And over the last one year, PANACEA BIOTECH share price is down 15.3%.
Today's Market
Sensex Ends 231 Points Higher; Capital Goods and FMCG Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours and ended their trading session on a positive note. At the closing bell, the BSE Sensex stood higher by 231 points (up 0.6%).
Related Views On News
PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)
Mar 27, 2019 | Updated on Mar 27, 2019Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)
Jan 17, 2020Don't fall for the safe stocks narrative going around in the stock market these days.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
The Best Asset Class to Invest in 2020 (Fast Profits Daily)
Jan 24, 2020Why I'm most bullish on this asset class above all else in 2020.
Small is Beautiful in 2020 (A Prediction You Don't Want to Miss) (Profit Hunter)
Jan 17, 2020As always Apurva will predict the best asset class to invest in in the coming year, last year he predicted gold and he was bang on! And this year he predicts... wait, you have to read to find out! Don't miss this.
The Smallcap Rebound Has Begun (13 Stocks Up Over 20% in the last Month) (Profit Hunter)
Jan 21, 2020The best smallcap stocks to bet on to get rich in this market rebound.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK PANACEA BIOTECH
- Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PANACEA BIOTECH
PANACEA BIOTECH - ACTAVIS COMPARISON
COMPARE PANACEA BIOTECH WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.